Skip to main content

Volume 6 Supplement 3

AIDS Vaccine 2009

P17-05. Dealing with HIV-1 diversity


One of the big roadblocks in development of HIV-1/AIDS vaccines is the enormous diversity of HIV-1, which could limit the value of any HIV-1 vaccine candidate currently under test.


To address the HIV-1 variation, we designed a novel T cell immunogen, designated HIVconsv, by assembling the 14 most conserved regions of the HIV-1 proteome into one chimaeric protein. Each segment is a consensus sequence from one of the four major HIV-1 clades A, B, C and D, which alternate to ensure equal clade coverage. The gene coding for the HIVconsv protein was inserted into a number of vaccine vectors, which were used in a multiple heterologous prime-boost combination.


Complex vaccination regimen induced strong, broad, polyfunctional HIV-1-specific CD8 and CD4 T cell responses non-human primates.


This vaccine approach provides an attractive and testable alternative for overcoming the HIV-1 variability, while focusing T cell responses on regions of the virus that are less likely to mutate and escape. Furthermore, this immunogen has merit in its simplicity. The potential of complex heterologous regimen will be discussed. Phase I clinical trials in healthy and HIV-1-infected individuals testing HIVconsv vaccines have been funded and are under preparation.

Author information

Authors and Affiliations


Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Rosario, M., Borthwick, N., Bridgeman, A. et al. P17-05. Dealing with HIV-1 diversity. Retrovirology 6 (Suppl 3), P287 (2009).

Download citation

  • Published:

  • DOI: